Valuation: Insulet Corporation

Market Cap 11.17B 9.8B 9.03B 8.35B 15.82B 1,065B 16.09B 108B 42.28B 522B 41.92B 41.02B 1,807B P/E 2026 *
26.1x
P/E 2027 * 20.3x
Enterprise Value 11.27B 9.89B 9.11B 8.42B 15.96B 1,075B 16.24B 109B 42.67B 527B 42.31B 41.4B 1,823B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 2.77x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+1.89%
1 week-1.95%
Current month+5.93%
1 month+8.10%
3 months-18.10%
6 months-44.20%
Current year-43.26%
1 week 152.78
Extreme 152.78
164.4
1 month 138.79
Extreme 138.79
167.82
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
01/07Other

Director

0 0%
01/07Free

Director

1,355 0.0019%
30/06Free

Director

144 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%-1.95%-44.26%-42.91% 11.17B
-0.50%-1.54%-28.85%-12.62% 164B
+1.80%+0.82%-6.73%-3.92% 107B
+0.32%+2.34%+2.79%+57.04% 59.04B
+0.79%-3.68%+39.99%+54.50% 51.72B
+0.72%-3.88%-13.66%-41.41% 41.87B
+0.47%-4.98% - - 34.7B
+2.66%+5.21%-10.09%-42.88% 28.93B
-1.10%-3.29%+55.70%-5.76% 24.99B
0.00%-1.01%-5.28%-3.57% 21.05B
Average +0.70%-1.30%-1.15%-4.61% 54.44B
Weighted average by Cap. +0.53%-0.99%-6.45%+0.06%

Financials

2026 *2027 *
Net sales 3.32B 2.91B 2.69B 2.48B 4.7B 317B 4.78B 32.06B 12.57B 155B 12.47B 12.2B 537B 3.93B 3.45B 3.18B 2.94B 5.57B 375B 5.66B 37.94B 14.88B 184B 14.76B 14.44B 636B
Net income 432M 379M 349M 323M 612M 41.21B 622M 4.17B 1.64B 20.18B 1.62B 1.59B 69.88B 564M 495M 456M 422M 799M 53.81B 813M 5.44B 2.14B 26.35B 2.12B 2.07B 91.24B
Net Debt 103M 89.92M 82.87M 76.6M 145M 9.78B 148M 989M 388M 4.79B 385M 376M 16.58B -283M -248M -229M -211M -401M -26.98B -407M -2.73B -1.07B -13.22B -1.06B -1.04B -45.76B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
10/07/26 USD 161.28 +1.89% 723,320
09/07/26 USD 158.29 +0.53% 1,069,987
08/07/26 USD 157.46 -2.53% 977,282
07/07/26 USD 161.55 +1.11% 935,125
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
161.28USD
Average target price
238.67USD
Spread / Average Target
+47.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock